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Summary Overexpression of the epidermal growth factor receptor (EGFR) and ErbB-2 has been observed in
a variety ofhuman tumours, making these receptors promising targets for directed tumour therapy. Since many
tumour cells express both ErbB-2 and EGFR and these receptors synergise in cellular transformation,
therapeutic reagents simultaneously binding to ErbB-2 and EGFR might offer advantages for tumour therapy.
We have previously described the potent anti-tumoral activity of a bispecific antibody toxin that contains
ErbB-2- and EGFR-specific single-chain Fv (scFv) domains. Here we report the construction and functional
characterisation of a novel bispecific recombinant toxin, scFv(FRP5)-TGFa-ETA. The fusion protein consists
of the antigen-binding domain of the ErbB-2-specific MAb, FRP5, and the natural EGFR ligand, TGFa,
inserted at different positions in truncated Pseudomonas exotoxin A. ScFv(FRP5)-TGFa-ETA protein displayed
binding to EGFR and ErbB-2, thereby inducing activation of the receptors, which was dependent on the
cellular context and the level of EGFR and ErbB-2 expression. The bispecific molecule was cytotoxic in vitro
for tumour cells expressing various levels of the target receptors. In vivo scFv(FRP5)-TGFoa-ETA potently
inhibited the growth of established A431 tumour xenografts in nude mice.
Keywords: single-chain Fv; transforming growth factor alpha; exotoxin A; growth factor receptor; directed
tumour therapy
Human tumours of epithelial origin often overexpress
members of the ErbB/epidermal growth factor receptor
(EGFR)-related family of receptor tyrosine kinases. This
receptor family comprises ErbB/EGFR, Neu/ErbB-2, ErbB-3
and ErbB-4 (reviewed in Peles and Yarden, 1993). In
particular, overexpression of EGFR and ErbB-2 has been
shown to contribute directly to malignancy (reviewed in
Gullick, 1991; Hynes and Stern, 1994). Owing to their
aberrant expression on tumour cells and their accessibility
from the extracellular space, these receptors are suitable
targets for directed cytotoxic therapy. Several recombinant
toxins have been described which consist of a target cell
recognition domain with specificity for EGFR or ErbB-2
genetically fused to the enzymatic domain of the bacterial
Pseudomonas exotoxin A (ETA). TGFa-PE40, a toxin fusion
protein carrying at the N-terminus the natural EGFR ligand
transforming growth factor (TGF) o, is cytotoxic for EGFR-
expressing tumour cells in vitro and in in vivo models of
human cancer (Pai et al., 1991). Anti-tumour activity of this
protein has recently been demonstrated in a phase I study in
a subset of patients with superficial bladder cancer (Goldberg
et al., 1995). A similar ETA fusion protein containing as a
target cell recognition domain a recombinant single-chain
Fv(scFv) fragment derived from EGFR-specific monoclonal
antibody (MAb) 225 (Kawamoto et al., 1983) displayed
cytotoxic activity in vitro and in animal models in vivo which
was highly selective for human tumour cells overexpressing
EGFR (Wels et al., 1995). No natural ligand is available
which binds ErbB-2 directly. Therefore, recombinant frag-
ments of ErbB-2-specific MAbs have been employed to direct
target cell specificity. ScFv-ETA fusion proteins containing
ErbB-2-specific binding domains have demonstrated highly
selective anti-tumour activity in vitro and in vivo (Wels et al.,
1992, 1995; Batra et al., 1992).
EGFR and ErbB-2 are often coexpressed in human
tumours. ErbB receptor tyrosine kinases undergo activation
after ligand binding and receptor dimerisation. Both the
EGFR ligand EGF as well as the ErbB-3 and ErbB-4 ligand
neu differentiation factor/heregulin, in addition to activation
of their cognate receptors, also induce ErbB-2 phosphoryla-
tion, most likely via ligand-induced heterodimerisation and
cross-phosphorylation (King et al., 1988; Plowman et al.,
1993; Sliwkowski et al., 1994). In experimental models
coexpression of ErbB-2/Neu and EGFR leads to the
synergistic transformation of cells (Kokai et al., 1989),
suggesting a role for receptor interaction in the development
of human malignancies. The anti-tumour activity of
recombinant toxins was enhanced by concurrently targeting
EGFR and ErbB-2. An additive cytotoxic effect has been
observed upon simultaneous treatment of tumour cells
coexpressing ErbB-2 and EGFR with the ErbB-2-specific
and EGFR-specific antibody toxins scFv(FRP5)-ETA and
scFv(225)-ETA (Wels et al., 1995). Likewise, scFv2(FRP5/
225)-ETA, a fusion toxin containing an ErbB-2-specific and
an EGFR-specific antibody domain fused to ETA in a single
polypeptide chain, was more potent than corresponding
monospecific toxins in the killing of human tumour cells
coexpressing ErbB-2 and EGFR in vitro and in vivo (Schmidt
et al., 1996).
Here we report the construction and functional character-
isation of a recombinant bispecific single chain toxin,
scFv(FRP5)-TGFa-ETA, containing a scFv antibody do-
main specific for ErbB-2 and the EGFR ligand TGFoa linked
to Pseudomonas exotoxin A. The fusion protein displayed
specific binding to ErbB-2 and EGFR resulting in the
activation of the kinase domains of both receptors.
ScFv(FRP5)-TGFx-ETA was cytotoxic in vitro for human
tumour cells expressing ErbB-2, EGFR or both target
antigens and displayed potent anti-tumour activity on
established A431 tumours in a nude mouse tumour model
in vivo.
Materials and methods
Cell lines
The SKBR3, MDA-MB453, MDA-MB468 and T47D human
breast tumour cell lines and the A431 human epidermoid
tumour cell line were maintained in Dulbecco's modified
Eagle medium (DMEM) containing 8% fetal calf serum
(FCS).
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cDNA synthesis and construction ofsingle chain toxins
Total RNA was extracted from the TGFo-expressing MDA-
MB-468 human breast carcinoma cells by the acid guanidium
thiocyanate-phenol-chloroform method (Chomczynski and
Sacchi, 1987). First strand cDNA synthesis, carried out using
a cDNA synthesis kit (Pharmacia Biotech, Brussels,
Belgium), was in a standard 33 MI reaction containing 5 ,g
total RNA and 0.2 Mg NotI-d(T)18 primer. For amplification
of the human TGFa cDNA and the introduction of a Hind
III restriction site at the 5' end and XbaI-SacI restriction site
at the 3' end of the cDNA, 2,l of the first strand cDNA
reaction was used as a template in a 50 MI polymerase chain
reaction (PCR) containing 25 pmol each of the two
oligonucleotides complementary to regions in the human
TGFa gene 5'-GACCCGAAGCTTGGTACCGGTGTGG-
TGTCCCATTTTAATG-3' and 5'-TTCTGGGAGCTCTC-
TAGAGAGGCCAGGAGGTCCGC-3', j4,l 2.5 mM dNTP
(N =G, A, T, C) mixture, 5 Ml 1Ox Vent DNA polymerase
buffer (New England Biolabs, Schwalbach, Germany), and
2.5 U of Vent DNA polymerase (New England Biolabs).
Vent DNA polymerase was added after initial denaturation
at 940C for 4 min. For 30 cycles annealing was performed for
1 min at 52°C, primer extension for 45 s at 72°C,
denaturation for 1 min at 94°C. PCR products were digested
with HindlIl and XbaI, or with Hindlll and Sacd, and the
expected 167 bp HindIII/XbaI and the 173 bp HindIll/SacI
TGFoa cDNA fragments encoding amino acids 1-50 of
human TGFac were isolated. The HindIII/XbaI TGFax cDNA
fragment was inserted into HindIII/XbaI digested plasmid
pSW202 (Wels et al., 1995), resulting in the expression
plasmid pSW202-TGFa encoding a fusion protein of amino
acids 1-50 of human TGFa and exotoxin A (ETA) amino
acids 252 to 613 (TGFa-ETA).
A Sacd restriction site was introduced into the exotoxin A
gene 5' of the ETA codon 380 by PCR as described above
using the plasmid pSW200 (Wels et al., 1995) as a template,
and two oligonucleotides, complementary to a region in the
ETA gene 5'-GCCGGGAGCTCTGCGGGCCCGGCGG-3',
and complementary to the non-coding vector region 3' of the
ETA gene insert in plasmid pSW200 5'-CTGTATCAGGCT-
GAAAATCTTCTC-3' respectively. PCR products were
digested with Sacd and BglII. The expected 814 bp Sacd!
BglII ETA DNA fragment encoding amino acids 380-613 of
ETA, the HindIII/SacI TGFoa cDNA fragment from the PCR
described above and pSW50 vector (Wels et al., 1995)
digested with HindIII/BglII were ligated. The resulting
plasmid encoding a fusion of TGFa amino acids 1-50 and
ETA amino acids 380-613 was digested with HindIII. A
HindlIl fragment encoding the ErbB-2-specific scFv(FRP5)
fused to amino acids 252-366 of ETA was derived from the
expression plasmid pMS240-5-225 encoding the bispecific
single chain antibody toxin scFv2 (FRP5/225)-ETA (Schmidt
et al., 1996), and inserted into the HindIII-digested TGFa-
ETA380 613 encoding plasmid. The integrity of the resulting
plasmid, pMS238-5-TGFa, encoding a fusion of scFv(FRP5),
ETA amino acids 252-366, human TGFax amino acids 1-50
and ETA amino acids 380-613 (scFv(FRP5)-TGFcx-ETA)
was confirmed by restriction analysis and DNA sequencing.
Bacterial expression andpurification of mono- and bispecific
single chain ETA fusion proteins
Plasmids encoding recombinant mono- and bispecific fusion
toxins were transformed into E coli CC1 18 (Wels et al.,
1995). Single colonies were grown overnight at 37°C in LB
medium containing 0.6% glucose and 100 jMg ml- ampicillin.
The culture was diluted 30-fold in the same medium, grown
at 37°C to an OD550 of 0.5 and induced with 0.5 mM IPTG
for 45 min at room temperature. Cells were harvested by
centrifugation at 10 000 g for 10 min at 4°C and the cell
pellet from 11 of culture was suspended in 15 ml of
phosphate-buffered saline (PBS) containing 6 M guanidine
hydrochloride and lysed by sonication. After incubation for
30 min at room temperature the lysate was clarified by
ultracentrifugation at 30 000 g for 30 min. The supernatant
was diluted to 3 M guanidine hydrochloride with PBS and
scFv-ETA proteins were purified by binding via the His
clusters included in the molecules to chelating sepharose
(Pharmacia Biotech, Brussels, Belgium) loaded with Ni2" and
equilibrated with 3 M guanidine hydrochloride and 20 mM
imidazole in PBS. Specifically bound proteins were eluted
with 3 M guanidine hydrochloride, 250 mM imidazole in PBS.
Fractions containing scFv-ETA proteins were pooled and
dialysed against PBS. Typical yield of purified proteins was
1 mg per 1 of original bacterial culture with a purity of
approximately 70% determined by SDS-PAGE and
Coomassie brilliant blue staining.
Binding assay
The binding of scFv(FRP5)-TGFa-ETA to ErbB-2 was
measured by enzyme-linked immunosorbent assay (ELISA).
Microtitre plates (96-well), coated with a recombinant protein
comprising the extracellular domain of ErbB-2 receptor
(kindly provided by M Jeschke) were blocked with 3%
bovine serum albumin (BSA) in Tris-buffered saline (TBS)
(10 mM Tris, pH 7.5, 150 mM sodium chloride). Aliquots of
50 4ul of scFv(FRP5)-TGFa-ETA, scFv(FRP5)-ETA (Wels et
al., 1995), or TGFoa-ETA at concentrations of 1 and 10 nM
were added to the wells and the plates were incubated for 1 h
at 37°C. Unbound scFv-ETA proteins were removed, the
wells were washed and incubated with 100 Ml rabbit anti-
exotoxin A serum for 1 h at 37°C followed by incubation
with 100 Ml of goat anti-rabbit IgG coupled to alkaline
phosphatase (Sigma, St Louis, MO, USA). The specifically
bound scFv-ETA proteins were detected by incubation with a
solution of 1 M Tris-HCl, pH 8.0, 1 mg ml-1 p-nitrophenyl-
phosphate disodium (Sigma) for 30 min at room temperature,
then the absorbance at 405 nm was measured.
Receptor activation assay
The biological activity ofthe TGFoadomain was determined via
induction of EGFR and ErbB-2 activation. NEI (Beerli et al.,
1994), SKBR3, MDA-MB453 and A431 cells were grown for
16 in DMEM containing 0.5% FCS. Purified recombinant
ETA fusion proteins were added at a concentration of
1 ,ig ml-' followed by incubation for 10 min at 37°C. Control
cells were treated with PBS or 100 ng ml-' EGF. Cells were
lysed in a buffer containing 50 mM Tris-HCl pH 7.5, 5 mM
EGTA, 150 mM sodium chloride, 10 jug ml-' aprotinin,
10 ig ml-' leupeptin, 1 mM phenylmethylsulphonyl fluoride
(PMSF), 2 mM sodium vanadate, 50 mM sodium fluoride,
50 mm sodium molybdate, 1% Triton X-100, 0.5% deso-
xycholate, 0.1% sodium dodecyl sulphate (SDS). Extracts were
clarified by centrifugation at 10 000 g for 10 min at 4°C.
Cleared cell lysates containing 15 Mg each oftotal proteins were
applied on a 7.5% sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE). After electrophoresis proteins
were blotted on a PVDF membrane (Millipore, Eschborn,
Germany) and phosphotyrosine-containing proteins were
detected by incubation of the membrane with an anti-
phosphotyrosine MAb as described (Harwerth et al., 1992),
followed by incubation with an anti-mouse horseradish
peroxidase-coupled antibody and chemiluminescent detection
with the ECL kit (Amersham, Aylesbury, UK).
Cell viability assay
The cell killing activity of ETA fusion proteins was measured
basically as described (Wels et al., 1992). The cells were
seeded in 96-well plates at a density of 1 x 104 cells per well in
normal growth medium. Various concentrations of ETA
fusion toxins were added to triplicate samples and the cells
were incubated for 40 h. Aliquots of 10 il of 10 mg ml-'
MTT (3-(4,5-dimethylthiazole-2-yl)-2,5 diphenyltetrazolium
bromide) (Sigma) in PBS were added to each well and theascFv(FRP5)
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cells were incubated for another 3 h. Cells were lysed for 3 h
by the addition of 90 Ml of 20% SDS in 50% dimethyl
formamide, pH 4.7. The OD at 590 nm of each sample was
determined in a microplate reader (Dynatech, Denkendorf,
Germany) as a measure of the relative amount of viable cells
compared with cells grown without the addition of
recombinant proteins.
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Figure 1 (a) Schematic structure of recombinant monospecific
and bispecific single chain toxins. The bacterially expressed
monospecific TGFa-ETA and scFv(FRP5)-ETA proteins consist
of amino acids 1-50 of human TGFa or the scFv domain of the
monoclonal antibody FRP5 containing the heavy (VH) and light
chain (VL) variable domains fused to amino acids 252-613 of
Pseudomonas exotoxin A (ETA) representing the translocation
domain II, domain Ib and domain III which mediates the ADP
ribosylation of the eukaryotic elongation factor 2. The bispecific
scFv(FRP5)-TGFa-ETA protein consists of the scFv(FRP5) and
TGFa domains connected via ETA amino acids 252-366
(domain II), fused to ETA amino acids 380 to 613 basically
representing domain III at the C-terminus. Included in the
molecules are the synthetic FLAG epitope and a cluster of 6 His
residues at the N-terminus, and clusters of 6 His residues N-
terminal ofeach ETA domain II facilitating the purification of the
proteins via Ni2+ affinity chromatography (not shown). (b) SDS-
PAGE analysis of mono- and bispecific single chain toxins
purified from E. coli lysates. The recombinant proteins were
expressed in E. coli CCl 18, purified via binding ofthe His clusters
included in the molecules to a Ni2+ column, and analysed by
SDS-PAGE and Coomassie staining. The positions of the
Competition experiments
A431 cells were used in a cell viability assay as described
above. The cells were grown for 40 h in the presence of
100 ng ml-1 scFv(FRP5)-TGFa-ETA in the absence or
presence of a 70-fold molar excess of MAbs FRP5, or 225,
or a combination of the two MAbs as competitors. The
relative amount of viable cells after treatment was determined
as described above.
In vivo anti-tumour activity ofscFv(FRP5)-TGFa-ETA
In vivo anti-tumour activity of the scFv(FRP5)-TGFa-ETA
and TGFax-ETA was tested using A431 squamous cell
carcinoma xenografts in athymic nude mice as described
(Schmidt et al., 1996). Approximately 25 mg of tumour tissue
was subcutaneously implanted in each mouse (5 mice per
group). Starting on day 6 after implantation, when the
tumour volume had reached approximately 100 mm3, the
mice were treated for 10 days with intraperitoneal injections
of 80 pmol of scFv(FRP5)-TGFa-ETA (5.8 jug) or TGFa-
ETA (3.8 jug) twice daily. The control group received PBS.
Tumour growth was followed by measuring two perpendi-
cular tumour diameters, the tumour volumes were calculated
and the data were statistically analysed.
Results
Construction and bacterial expression of TGFx-ETA and
scFv(FRP5)-TGFa-ETA
cDNA encoding amino acids 1 to 50 ofTGFa was derived by
reverse transcription of mRNA isolated from TGFa-
producing MDA-MB468 human breast carcinoma cells and
subsequent amplification by the polymerase chain reaction
with specific oligonucleotide primers introducing restriction
sites at the 5' and 3' ends of the cDNA. A monovalent fusion
of TGFc with truncated Pseudomonas exotoxin A, lacking
the original cell binding domain Ta of the toxin, was
constructed by introducing the TGFa cDNA fragment 5' of
the ETA gene in the previously described expression plasmid
pSW202 (Wels et al., 1995). The resulting plasmid was
designated pSW202-TGFa and encodes a protein very similar
to the previously described TGFcx-PE40 (Siegall et al., 1989).
A bivalent fusion containing the ErbB-2-specific single chain
antibody scFv(FRP5), ETA amino acids 252-366, TGFa
and ETA amino acids 380-613, was constructed as described
in detail in Materials and methods by stepwise assembly of
DNA fragments encoding scFv(FRP5)-ETA252 366 (Schmidt
et al., 1996), TGFa and ETA380 613 in the expression plasmid
pSW50 (Wels et al., 1995). The resulting expression plasmids,
pSW202-TGFax encoding monovalent TGFc-ETA and
pMS238-5-TGFae encoding the bivalent scFv(FRP5)-TGFoc-
ETA, contain an IPTG-inducible tac promoter followed by
sequences encoding the ompA signal peptide, the synthetic
FLAG epitope, six His residues, followed in the case of
TGFa-ETA by TGFoa, six His residues and ETA amino acids
252-613 or, in the case of scFv(FRP5)-TGFo-ETA by the
67 kDa scFv(FRP5)-ETA protein (lane 1), the 47 kDa TGFa-
ETA protein (lane 2) and the 73 kDa scFv(FRP5)-TGFa-ETA
protein (lane 3) are indicated. M, molecular weight standards.Bispecific antibody-growth factor toxin
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scFv(FRP5), six His residues, ETA amino acids 252-366,
TGFx and ETA amino acids 380-613. The structure of the
monovalent and bivalent fusion proteins used in this study is
shown schematically in Figure la.
The recombinant toxins TGFa-ETA, scFv(FRP5)-TGFa-
ETA, and the previously described scFv(FRP5)-ETA (Wels
et al., 1992, 1995) were expressed in E. coli and purified as
described in Materials and methods. SDS-PAGE analysis
of the purified material revealed a purity of greater than
70% after a single round of Ni2" affinity purification
(Figure Ib).
Binding properties ofscFv(FRP5)-TGFx-ETA
The recombinant scFv(FRP5)-TGFa-ETA was tested for its
ability to bind to human ErbB-2 in ELISA experiments. The
bivalent scFv(FRP5)-TGFa-ETA at concentrations of 1 and
10 nM was added to the wells of 96-well plates coated with
purified recombinant extracellular domain of ErbB-2, the
plates were incubated at 37°C for 1 h and specifically bound
protein was determined. The monovalent ErbB-2-specific
fusion protein scFv(FRP5)-ETA (Wels et al., 1992, 1995)
and EGFR-specific TGFa-ETA served as controls. The
results are shown in Figure 2a. Both the bivalent
scFv(FRP5)-TGFa-ETA and the monovalent scFv(FRP5)-
ETA bound specifically to recombinant ErbB-2, whereas no
specific binding of the growth factor toxin TGFa-ETA was
observed.
The ability of the TGFa-containing toxins, scFv(FRP5)-
TGFax-ETA and TGFa-ETA, to bind to and activate EGFR
was tested on NEl murine fibroblasts expressing human
EGFR cDNA (Beerli et al., 1994). NEl cells were treated for
10 min at 37°C with the bivalent scFv(FRP5)-TGFa-ETA, or
the monovalent TGFa-ETA and scFv(FRP5)-ETA. Control
cells were treated with PBS or 100 ng ml-' EGF. Equal
amounts of cell lysates were assayed for their phosphotyr-
osine content by SDS-PAGE and subsequent immunoblot-
ting with a specific anti-phosphotyrosine antibody (Harwerth
et al., 1992). The results are shown in Figure 2b. Treatment
of cells with EGF (lane 2), TGFa-ETA (lane 4) or
scFv(FRP5)-TGFa-ETA (lane 5) led to a strong increase in
the phosphotyrosine content of a protein corresponding in
size with the 170 kDa EGFR, which was confirmed by
reprobing the filter with an anti-EGFR serum (Figure 2b,
bottom). PBS and the monovalent ErbB-2-specific
scFv(FRP5)-ETA had no effect on the phosphotyrosine
content of the receptor (lanes 1 and 3). The results show
that in contrast to the ErbB-2-specific antibody toxin
scFv(FRP5)-ETA, the bivalent scFv(FRP5)-TGFo-ETA and
the monovalent TGFoa-ETA bind to and activate EGFR.
In vitro cell killing activity ofscFv(FRP5)-TGFax-ETA
We tested the cell killing activity of the bispecific
scFv(FRP5)-TGFa-ETA on human tumour cell lines expres-
sing different levels of ErbB-2 and EGFR as shown in Table
I. A431 human squamous cell carcinoma cells and the human
a
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Figure 2 (a) Binding of scFv(FRP5)-TGFa-ETA to recombinant
extracellular domain of ErbB-2. Immobilised extracellular domain
of ErbB-2 was incubated with scFv(FRP5)-ETA (L=),
scFv(FRP5)-TGFa-ETA ( ) or TGFa-ETA ( ) at concen-
trations of 1 nm or 10 nm. The amount of specifically bound
protein was measured after incubation with rabbit anti-ETA
serum, followed by alkaline phosphatase-coupled goat anti-rabbit
IgG and conversion of the phosphatase substrate p-nitrophenyl-
phosphate as the absorbance at 405 nm. (b) ScFv(FRP5)-TGFa-
ETA- and TGFa-ETA-induced tyrosine phosphorylation of
EGFR in NEI murine fibroblasts. The cells were grown in low
serum for 16 h and then incubated with 1 jig ml-1 scFv(FRP5)-
ETA (lane 3), TGFa-ETA (lane 4) or scFv(FRP5)-TGFa-ETA
(lane 5) for 10 min. Control cells were treated with PBS (lane 1)
or 100 ng ml- 1 EGF (lane 2). Equal amounts of cell lysates were
analysed by SDS-PAGE and immunoblotting with an anti-
phosphotyrosine MAb, followed by incubation with an anti-
mouse horseradish peroxidase-labelled antibody and chemilumi-
nescent detection (top). The amount ofEGFR loaded in each lane
was analysed by reincubation of the filter with 12E EGFR specific
antiserum (bottom). The position of the 170 kDa EGFR is
indicated (EGFR). M, molecular weight standards.
Table I In vitro cell killing activity of ETA fusion proteins
bb ~~~~~~~~~~~~~IC5o (nM)a
Cell line EGFRb ErbB-2b TGFx-ETA scFv(FRPS)-ETA scFv(FRP5)-TGFa-ETA scFv2(FRP5/225)-ETA
A431 + + + + + + <0.02 0.52 0.04 0.02c
MDA-MB468 + + + + + +/ 0.02 >15 0.42 3.04c
MDA-MB453 +/ + + + + 0.53 <0.01 <0.01 NDd
T47D + + + 2.23 0.13 0.82 ND
SKBR3 + + + + + 1.66 0.34c 1.24 0.32C
aIC50 values were determined in an enzymatic cell viability assay as described in Materials and methods. The data are calculated from Figure 3.
bRelative levels of receptor expression were determined by quantitative immunoblot analysis with ErbB-2- and EGFR-specific antibodies (not
shown). cSchmidt et al. (1996). d, not done.
IVI
Anti-EGFRBispecific antibody-growth factor toxin
M Schmidt and W Wels m
857
10
Concentration (nM)
A431
120
110
100
90
80
70
60
50
40
30
20
10
v
10 100 0.01
Concentration (nM)
0.1
MDA-IMB468
I III III
0.1 1 10 100
Figure 3 Inhibition of the growth of human tumour cell lines by recombinant single chain toxins. MDA-MB453, T47D and MDA-
MB468 human breast carcinoma cells, and A431 human squamous cell carcinoma cells were incubated for 40 h with the indicated
concentrations of scFv(FRP5)-TGFLa-ETA (0), scFv(FRP5)-ETA (U), or with TGFac-ETA (A). The relative number of viable cells
was determined using an enzymatic assay described in Materials and methods and is indicated as the absorption at 590 nm. Each
point represents the mean of a set of data determined in triplicate in three independent experiments.
breast carcinoma cell lines MDA-MB453, MDA-MB468 and
T47D, were incubated for 40 h with various concentrations of
the bispecific scFv(FRP5)-TGFa-ETA and the corresponding
monospecific toxins, scFv(FRP5)-ETA and TGFa-ETA. The
relative number of viable cells was determined with an
enzymatic assay (Wels et al., 1992). The results are shown in
Figure 3 and the IC50 values are summarised in Table I.
ScFv(FRP5)-TGFa-ETA was cytotoxic for the five cell
lines tested. The monospecific scFv(FRP5)-ETA and the
bispecific scFv(FRP5)-TGFa-ETA showed similar activity on
MDA-MB453 cells overexpressing ErbB-2. Both toxins
displayed a greater than 50-fold higher cell killing activity
than the EGFR-specific TGFx-ETA, with IC50 values of less
than 0.01 nM vs 0.53 nM respectively. Similarly, T47D cells
were more sensitive to the toxins containing the ErbB-2-
specific scFv than they were to TGFa-ETA, with IC50 values
of 0.13, 0.82 and 2.23 nm for scFv(FRP5)-ETA, scFv(FRP5)-
TGFa-ETA and TGFa-ETA respectively. On A431 cells
expressing high levels of EGFR and low levels of ErbB-2,
scFv(FRP5)-TGFax-ETA was 13 times more active than
scFv(FRP5)-ETA, but less active than TGFoa-ETA, with
IC50 values of 0.04, 0.52 and less than 0.02 nM respectively.
This is in contrast to another bivalent ETA fusion protein,
scFv2(FRP5/225)-ETA, which contains two scFv domains
specific for ErbB-2 and EGFR and was more active on A431
cells than either of the corresponding monospecific scFv-
toxins (Schmidt et al., 1996, and Table I). Treatment of A431
cells with EGF did not result in significant cell death at
concentrations below 3 nm indicating that the high cell killing
activity of the TGFa-containing fusion proteins observed at
low concentrations was a result of their toxin domain (data
not shown). As previously reported, EGFR-overexpressing
MDA-MD468 cells were not sensitive to the ErbB-2-specific
scFv(FRP5)-ETA at the concentrations tested (Wels et al.,
1995; Schmidt et al., 1996). However, they were killed by
TGFa-ETA and scFv(FRP5)-TGFa-ETA with IC50 values of
0.02 and 0.42 nM respectively. ScFv(FRP5)-TGFax-ETA was
approximately seven times more active than the previously
described bispecific antibody toxin scFv2(FRP5/225)-ETA on
MDA-MB468 cells (Schmidt et al., 1996). In contrast,
scFv(FRP5)-TGFx-ETA was less active than scFv2(FRP5/
255)-ETA on A431 cells (Table I).
Competition of scFv(FRP5)-TGFa-ETA cytotoxicity
Competition experiments were carried out in order to
determine the contribution of the individual binding
domains to the cytotoxic activity of the bispecific
scFv(FRP5)-TGFa-ETA molecule. A431 cells were treated
for 40 h with 100 ng ml-1 scFv(FRP5)-TGFa-ETA in the
absence or presence of a 70-fold molar excess of the EGFR-
specific MAb 225, which has previously been shown to
compete the binding of EGF and TGFa to EGFR
(Kawamoto et al., 1983), the parental ErbB-2-specific
antibody FRP5 (Harwerth et al., 1992), or a mixture of
both. Cell viability was measured in comparison with PBS-
treated cells. The results are shown in Figure 4. A total of
90.5% of the cells were killed by scFv(FRP5)-TGFo-ETA in
the absence of competitor. In the presence of an excess of
MAb 225, the cell killing activity was reduced resulting in
65.8% cell killing. The ErbB-2-specific MAb FRP5 alone had
only little effect on scFv(FRP5)-TGFaC-ETA activity (84.5%
MDA-MB453
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225 FRP5 immunoblotting with anti-phosphotyrosine MAb, an increase
+225 in ErbB-2 phosphotyrosine content was detected in A431 cells
treated with EGF, TGFa-ETA or bispecific scFv(FRP5)-
TGFa-ETA, but not in cells treated with the monospecific
scFv(FRP5)-ETA (data not shown).
The effects of several fusion toxins binding to EGFR,
ErbB-2, or both, on the activation of ErbB-2 was analysed in
SKBR3 cells. These cells express approximately 1 x 106 ErbB-
2 and 9 x 104 EGFR molecules. The cells were treated for
10 min at 37°C with the bispecific antibody toxin
scFv2(FRP5/225)-ETA, scFv(FRP5)-TGFoa-ETA, the mono-
valent antibody toxins, scFv(225)-ETA or scFv(FRP5)-ETA,
or TGFa-ETA. Control cells were treated with PBS or
Figure 4 Inhibition of scFv(FRP5)-TGFc
activity by competition with monoclonal
human squamous cell carcinoma cells were
with 100 ng ml - 1 scFV(FRP5)-TGFa-ETA v
of competitor or in the presence of a 70-fold
ErbB-2-specific MAb FRP5, or EGFR-speci
combination of both as indicated. The relativ
cells was determined as described in Figure
and methods. Each point was determined
standard deviation is represented by error ba
cell killing), since A431 cells express appr(
more EGF receptor than ErbB-2 and I
remain accessible for the toxin. However.
competing antibodies reduced the cell
scFv(FRP5)-TGFa-ETA even further thz
(36.5% cell killing). These results indicatl
domains contribute to the cell killing acti'
TGFa-ETA, with the TGFa domain bei
for its activity on A431 cells, which exj
EGFR and low levels of ErbB-2. S
experiments were carried out with the n
ETA. As expected, only MAb 225, but n
to a reduction of TGFax-ETA cell killini
shown).
Activation of receptor tyrosine kinases upt
scFv(FRP5)-TGFaL-ETA binding
Type I receptor tyrosine kinases undergc
cytoplasmic kinase domain upon ligand b
dimerisation. Ligand-induced activation o
to the formation of EGFR homodimer;
formation of EGFR/ErbB-2 heterodimei
1990; Wada et al., 1990), as well
heterodimers (Soltoff et al., 1994). The
toxin scFv2 (FRP5/225)-ETA, containing
binding domains, activates both receptors
express high levels of EGFR and lo,
(Schmidt et al., 1996). In contrast,
monovalent antibody toxins specific for
were unable to induce receptor activatior
We analysed the effect of TGFx-ETA
TGFa-ETA on the activation of EGFR
cells were treated for 10 min at 37°C
TGFx-ETA, TGFa-ETA or scFv(FRP5)-
were treated with PBS or 100 ng ml-1 E(
of cell lysates were assayed for their phos
by SDS -PAGE and subsequent immi
specific anti-phosphotyrosine antibody. TI
in Figure Sa. Treatment of cells with EC
ETA (lane 4), or the bispecific scFv(FRP.
5) led to a strong increase in the phosph(
a protein corresponding in size with th
which was confirmed by reprobing the
EGFR serum (Figure Sa, bottom). PBS
scFv(FRP5)-ETA protein had no effect
osine content of the receptor (lanes 1 anc
immunoprecipitation with an ErbB-2-spe
WA A I_j I. ..., . . -W-.A I I -__.. I, I . _. _ _ _ ,, _
100 ng ml-1 EGF. Phosphotyrosine content of cellular
a-ETA cell killing proteins was determined by immunoblot analysis (Figure
antibodies. A431 5b). A phosphotyrosine-containing protein corresponding in
incubated for 40 h size with the 185 kDa ErbB-2 was already observed in
vithout the addition unstimulated SKBR3 cells treated with PBS (lane 1). The
.molar excess of the identity of this protein was confirmed by reprobing the filter
iel number of viable with an anti-ErbB-2 serum (Figure 5b, bottom). Treatment of
3 and in Materials cells with EGF (lane 2), TGFa-ETA (lane 6) or scFv(FRP5)-
in triplicate. The TGFoa-ETA (lane 7) led to a further increase in ErbB-2
Lrs. phosphotyrosine content. No significant effect on ErbB-2
activation was observed after treatment of cells with
scFv(FRP5)-ETA (lane 3), scFv(225)-ETA (lane 4) or
scFv2(FRP5/225)-ETA (lane 5).
oximately 100 times The effects of bispecific toxins on the activation of ErbB-2
the EGF receptors was analysed further in MDA-MB453 cells. These cells express
a mixture of both high levels of ErbB-2, ErbB-3 and ErbB-4, but very low levels
killing activity of of EGFR (Jeschke et al., 1995). The cells were treated for
an MAb 225 alone 10 min at 37°C with scFv2(FRP5/225)-ETA, scFv(FRP5)-
e that both binding TGFa-ETA, TGFa-ETA, or the previously described ErbB-3/
vity of scFv(FRP5)- ErbB-4-specific heregulin fusion protein HRG/1-ETA
ing more important (Jeschke et al., 1995). Control cells were treated with PBS or
press high levels of 100 ng ml-' EGF. Phosphotyrosine content of cellular
,imilar competition proteins was determined by immunoblot analysis (Figure
nonospecific TGFa- 5c). Treatment of cells with HRGj3-ETA (lane 6) led to a
tot MAb FRP5, led strong increase in the phosphotyrosine content of a protein
g activity (data not corresponding in size with the 185 kDa ErbB-2, which was
confirmed by reprobing the filter with an anti-ErbB-2 serum
(Figure 5c, bottom). The bispecific toxins, scFv2(FRP5/225)-
gn ETA (lane 3) and scFv(FRP5)-TGFae-ETA (lane 4), weakly
stimulated ErbB-2 phosphorylation, whereas PBS (lane 1),
EGF (lane 2) and the monospecific TGFax-ETA had no effect
activation of their on the phosphotyrosine content of the receptor in MDA-
)inding and receptor MB453 cells. The results show that the bispecific toxins,
If EGFR in addition scFv(FRP5)-TGFe-ETA and scFv2(FRP5/225)-ETA, and the
s also leads to the monospecific growth factor toxins, TGFoa-ETA and HRGfl-
rs (Goldman et al., ETA, but not the monospecific antibody toxin scFv(FRP5)-
as EGFR/ErbB-3 ETA, induce the activation ofEGFR and/or ErbB-2. Thereby,
bispecific antibody the activity of the proteins is dependent on the cellular context
ErbB-2 and EGFR and the expression level of ErbB receptor family members.
in A431 cells which
v levels of ErbB-2
the corresponding
EGFR or ErbB-2
1.
k and scFv(FRP5)-
in A431 cells. The
with scFv(FRP5)-
ETA. Controls cells
GF. Equal amounts
,photyrosine content
anoblotting with a
he results are shown
hF (lane 2), TGFca-
5)-TGFoc-ETA (lane
otyrosine content of
e 170 kDa EGFR,
filter with an anti-
and the monovalent
on the phosphotyr-
J 3). Similarly, after
cific antiserum and
Inhibition of tumour cell growth in vivo
The in vivo anti-tumour activity of scFv(FRP5)-TGFa-ETA
and TGFcx-ETA was tested on A431 xenografts in nude mice.
A431 tumour tissue (25 jug) was implanted s.c. into three
groups of five mice on day 0. Six days later, when the
tumours had reached approximately 100 mm3 in size,
treatment was begun. The mice received twice daily
intraperitoneal injections of 80 pmol of scFv(FRP5)-TGFax-
ETA or TGFa-ETA for a total of 10 days. Control mice
received PBS. The results are shown in Figure 6a. Treatment
with both fusion toxins led to the inhibition of A431 tumour
growth during treatment to a similar extent. By day 22, when
the experiment was terminated, the size of the tumours in the
scFv(FRP5)-TGFa-ETA and TGFa-ETA treated animals
was, respectively, 21% and 22% of the tumour size in the
control group. A transient weight loss of less than 10% was
observed during the course of the TGFa-ETA treatment
(Figure 6b). Weight loss of less than 5% was observed in the
scFv(FRP5)-TGFa-ETA-treated animals. All animals recov-
ered quickly after the end of the treatment.
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Figure 5 ScFv(FRP5)-TGFo-ETA and TGFa-ETA-induced tyrosine phosphorylation of EGFR and ErbB-2. (a) A431 cells were
grown in low serum for 16 h and then incubated with 1 ,g ml-1 scFv(FRP5)-ETA (lane 3), TGFa-ETA (lane 4), or scFv(FRP5)-
TGFa-ETA (lane 5) for 10 min. Control cells were treated with PBS (lane 1) or 100 ng ml-1 EGF (lane 2). Equal amounts of cell
lysates were analysed by SDS-PAGE and immunoblotting with an anti-phosphotyrosine MAb (top) or with 12E EGFR-specific
antiserum (bottom) as described in the legend for Figure 2b. The position of the 170 kDa EGFR is indicated (EGFR). (b) SKBR3
human breast carcinoma cells were grown in low serum as described above and then treated with 1 ig ml- 1 scFv(FRP5)-ETA (lane
3), EGFR-specific antibody toxin scFv(225)-ETA (lane 4), the bispecific antibody toxin scFv2(FRPS/225)-ETA (lane 5), TGFaC-ETA
(lane 6), or scFv(FRP5)-TGFx-ETA (lane 7) for 10 min. Control cells were treated with PBS (lane 1) or 100 ng ml-1 EGF (lane 2).
Equal amounts of cell lysates were analysed by SDS-PAGE and immunoblotting with an anti-phosphotyrosine MAb (top) as
described in the legend for Figure 2b or with 21N ErbB-2-specific antiserum (bottom). The position of the 185 kDa ErbB-2 is
indicated. (c) MDA-MB453 human breast carcinoma cells were grown in low serum as described above and then treated with
1 jig ml- bispecific antibody toxin scFv2(FRP5/225)-ETA (lane 3), EGFR-specific TGFLa-ETA (lane 4), the bispecific scFv(FRP5)-
TGFa-ETA (lane 5), or the ErbB-3/ErbB-4-specific heregulin fusion protein HRG,B1-ETA (lane 6) for 10 min. Control cells were
treated with PBS (lane 1) or 100 ng ml-
1 EGF (lane 2). Equal amounts of cell lysates were analysed by SDS-PAGE and
immunoblotting with an anti-phosphotyrosine MAb (top) as described in the legend for Figure 2b or with 21N ErbB-2-specific
antiserum (bottom). The position of the 185 kDa ErbB-2 is indicated. M, molecular weight standards.
Discussion
Overexpression of EGFR and ErbB-2 has been observed in a
variety of human tumours making these receptors promising
targets for directed tumour therapy (reviewed in Gullick,
1991; Hynes and Stern, 1994). Several recombinant
Pseudomonas exotoxin A fusion proteins binding to EGFR
or ErbB-2 have been described (Chaudhary et al., 1987; Wels
et al., 1992, 1995; Batra et al., 1992). Since many tumour cells
express both ErbB-2 and EGFR, therapeutic reagents binding
to both receptor proteins might offer advantages over
monospecific molecules by inducing the formation of
receptor heterodimers which in turn might lead to more
rapid uptake of toxin-receptor complexes. We have recently
characterised scFv2(FRP5/225)-ETA, a bispecific antibody
toxin, which contains, in a single polypeptide chain, ErbB-2-
and EGFR-specific scFv domains linked to Pseudomonas
exotoxin A (Schmidt et al., 1996). This molecule was
cytotoxic in vitro and in vivo for tumour cells expressing
EGFR, ErbB-2 or both receptor proteins.
Here we describe the construction and functional
characterisation of another bispecific recombinant toxin,
scFv(FRP5)-TGFx-ETA binding to ErbB-2 and EGFR.
The fusion protein consists of the antigen-binding domains
EGFR-'Bispecific antibody-growth factor toxin
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Figure 6 Effect of recombinant single chain toxir
growth of A431 tumour xenografts in nude mice
tissue (25 ,ug) were implanted subcutaneously intc
mice per group). Six days later the mice received i
80 pmol TGFa-ETA (A) or scFv(FRP5)-TGFa-
daily for 10 days. The control group received
Tumour size and (b) body weight were measured
times and tumour volumes were calculated. The l
each group are shown.
of the ErbB-2-specific MAb FRP5 and the
ligand TGFoc linked to truncated Pseudomon
We have shown that the scFv(FRP5)-TGF
binds to EGFR and ErbB-2 and is cytotoxic I
expressing various levels of the target recept(
presence of two cell recognition domains
molecule is very similar in size to the pa
specific antibody toxin scFv(FRP5)-ETA (73
much smaller than the previously descr
antibody toxin scFv2(FRP5/225)-ETA (107 kI
allow better tumour penetration and faster
(Colcher et al., 1990).
The different biological activities of ET,
target cell recognition, translocation to ti
enzymatic activity reside in separate protein
function independently (Hwang et al., 1987).
insertion of foreign protein sequences a
boundaries. Although insertion at certain
result in reduced cytotoxic activity, Pseudoi
A has proved to be surprisingly flexible
possible integration sites for small heterologous binding
domains. ETA fusion proteins containing TGFa, either N-
terminal of the ETA translocation domain II (Siegall et al.,
1989) similar to TGFcx-ETA in our study, or at the C-
terminus of the enzymatic domain III (Chaudhary et al.,
1987), have been derived and were biologically active. The
activity of proteins with a heterologous binding domain
inserted between domains II and III of ETA seems to be
dependent upon the size and/or nature of the ligand. The 50
amino acid TGFa domain located between translocation and
enzymatic domains in the bispecific scFv(FRP5)-TGFa-ETA
retains binding activity, whereas the 27 kDa ErbB-2-specific
scFv(FRP5) domain inserted at the same position results in a
fusion toxin with drastically reduced cytotoxic activity
(Schmidt and Wels, unpublished data).
Internalisation of toxin-receptor complexes and subse-
quent intracellular processing of the ETA domain is a
prerequisite for the cytotoxic activity of recombinant fusion
toxins (Ogata et al., 1992). TGFa-containing growth factor toxins, but not the monospecific antibody toxins,
scFv(FRP5)-ETA (anti-ErbB-2) and scFv(225)-ETA (anti-
EGFR), activate ErbB-2 or EGFR upon binding, suggesting
that the scFv-ETA proteins cannot induce receptor dimerisa-
tion and activation (Schmidt et al., 1996). Cellular uptake of
these antibody toxins therefore is dependent on the intrinsic
turnover rate of the target receptors. In contrast, bispecific
scFv(FRP5)-TGFa-ETA induced tyrosine phosphorylation of
both EGFR and ErbB-2. Activation of the receptors upon
binding might also result in more rapid internalisation of the
bispecific toxin. Since activation of ErbB-2 and EGFR to a
similar degree was also observed after treatment of A431 and
SKBR3 cells with monospecific TGFa-ETA and EGF, it
remains unclear to what extent EGFR/ErbB-2 heterodimer-
isation and activation in these cells is dependent on the
additional ErbB-2-specific scFv domain in the bispecific
molecule. In agreement with a previous report (Jeschke et
al., 1995) in MDA-MB453 cells expressing less than 5000
EGFR molecules, HRG,B-ETA, a fusion toxin containing
the EGF-like domain of the ErbB-3/ErbB-4 ligand heregulin
IL i ,/I,1#1, but not TGFx-ETA or EGF were able to induce tyrosine
20 22 24 phosphorylation of ErbB-2. This suggests that in these cells
transmodulation of ErbB-2 does not occur via interaction
with EGFR but mostly via interaction with ErbB-3 and/or
is on the in vivo ErbB-4. Similar results have been observed in cells expressing
e. A431 tumour either ErbB-2 and ErbB-3, or ErbB-2 and ErbB-4 in the
p each mouse (5 complete absence of EGFR (Riese et al., 1995). However, i.p. injections of both bispecific toxins, scFv(FRP5)-TGFa-ETA and
PBS (0) (a) scFv2(FRP5/225)-ETA, were able to induce activation of
at the indicated ErbB-2 in MDA-MB453 cells. Thereby the much lower level
mean values for of ErbB-2 tyrosine phosphorylation in comparison with that
after treatment with HRG,B1-ETA probably reflects the very
limited numbers of EGFR which are present in MDA-
MB453 cells and could be recruited for ErbB-2/EGFR
heterodimers. Our data suggest that such artificial ligands,
natural EGFR after removal of the toxic effector domain, might also be
ias exotoxin A. useful in studying signal transduction and growth-modulating
'a-ETA protein activities of defined receptor heterodimers even when such
for tumour cells dimers are not normally induced in a specific cell line by
Drs. Despite the natural ligands of the ErbB receptor family.
this bispecific Interestingly, scFv(FRP5)-TGFa-ETA, despite the low
irental ErbB-2- abundancy of EGFR, displayed much higher cell killing
vs 67 kDa) and activity on MDA-MB453 cells than on the other cell lines
ribed bispecific tested. Its activity equalled that of the ErbB-2-specific
Da). This might scFv(FRP5)-ETA, whereas on EGFR-overexpressing A431
blood clearance and MDA-MB468 cells, bispecific scFv(FRP5)-TGFae-ETA in
vitro was less active than monospecific TGFa-ETA. This
A required for suggests that reduced binding activity of the TGFa domain in
ie cytosol and the bispecific molecule rather than reduced scFv(FRP5)
domains which binding or a loss of activity of the ETA portion might be
This allows the responsible. Similarly, a fusion protein containing TGFa and
It the domain an anti-Tac scFv, both located at the N-terminus of ETA
positions can domains II, lb and III, was less active on EGFR-
monas exotoxin overexpressing A431 cells than a monospecific TGFa fusion
with regard to toxin (Batra et al., 1990).
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ScFv(FRP5)-TGFx-ETA displayed potent in vivo anti-
tumour activity against established A431 xenografts in nude
mice. In contrast to its activity on A431 cells in vitro, the
bispecific molecule was as active in vivo as the monospecific
TGFx-ETA. The observed anti-tumoral activity was specific
for the fusion proteins since in a similar experiment,
treatment of the animals with the truncated ETA portion
alone lacking a cell binding domain had no effect on tumour
growth (Schmidt et al., unpublished results). Some normal
tissues including hepatocytes express significant numbers of
EGFR which could complicate the application of TGFx
containing toxins in vivo (Real et al., 1986). Systemic
treatment of mice with high doses of TGFx-PE40, a fusion
toxin very similar to the TGFxz-ETA used in this study,
resulted in fatal liver damage, thus limiting the amount of
toxin which could be applied safely (Pai et al., 1991). In order
to avoid systemic toxicity in a recent clinical study of TGFx-
PE40 (TP40) in superficial bladder cancer, the molecule was
applied directly into the bladder by transurethral instilation
(Goldberg et al., 1995). The treatment was well tolerated by
the patients indicating that local treatment, where applicable,
could be a way to circumvent systemic toxicity. In our study
there were no fatal effects in mice after i.p. injection of
TGFx-ETA at the applied dose but we observed weight loss
which was transient and subsided quickly after treatment was
terminated. Weight loss was also observed in animals treated
with the bispecific scFv(FRP5)-TGF.-ETA, but it was less
pronounced suggesting that normal tissues expressing EGFR
might tolerate the bispecific molecule better. This could be
due to reduced binding activity of the intramolecular TGFcf
domain and/or improved tumour targeting owing to the
additional tumour-specific scFv domain.
OurresultsshowthatascFvantibodydomainandtheTGFx
growth factor domain inserted at different locations in
Pseudomonas exotoxin A result in a bispecific toxin which
binds to both ErbB-2 and EGFR tyrosine kinases. The fusion
proteindisplays in vitroandin vivocell killingactivity onhuman
tumour cells expressing both target antigens on their surface.
The coexpression of ErbB-2 and EGFR observed in many
human tumours and their synergistic interaction in the
transformation of cells provides a rationale for the further
developmentofsuchbispecificreagentsforclinicalapplications.
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